DGAP-News: co.don AG

CO.DON - First Spherox patient in the UK

Berlin / Teltow, 26 March 2018 - The Royal Orthopaedic Hospital Birmingham, one of the leading orthopaedic centres, is the first hospital in the UK to start treating patients with the 100% autologous cartilage cell transplant Spherox. CO.DON has received the first biopsy for the cultivation of regenerative articular cartilage. As anticipated this is the first patient being treated with the EMA authorised product outside of Germany.

Ralf Jakobs, chairman of the board of CO.DON AG: " We have all been waiting a long time for the first biopsy of our product from other European countries and here from the eminently important English market. This is an absolutely important milestone on the way to implementing the corporate strategy. It implements regulatory and legal requirements in one of our most important European target markets. Together with the hospital partners we have successfully fulfilled all the national legal and regulatory requirements to enable patients to receive personalized healing. Other hospitals are ready to regeneratively and long-lasting treat patients with knee cartilage defects throughout the UK with Spherox."

CO.DON develops, produces and markets autologous cell therapies for the minimally-invasive repair of cartilage defects in the knee following traumatic or degenerative defects. Spherox is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). The treatment has been used in over 200 clinics to treat more than 12,000 patients. In July 2017 the company received EU marketing authorisation for Spherox. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs.

Further information: www.codon.eu

Investor Relations and Press Contact:
Matthias Meißner, M.A.
Corporate communications / IR / PR
Tel. +49 (0)30 240352330
Fax +49 (0)30 240352309
Email: ir@codon.de
E-Mail: ir@codon.de